AlphaCrest Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

AlphaCrest Capital Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-27,171	Closed	-$320K	–	1311
2020 Q3	$320K	Buy	27,171 +10,832	+66%	+$132K	0.03%	827
2020 Q2	$241K	Buy	+16,339	New	+$242K	0.04%	742
2019 Q3	–	Sell	-16,286	Closed	-$481K	–	1367
2019 Q2	$481K	Buy	+16,286	New	+$628K	0.04%	709

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

AlphaCrest Capital Management's AERI Position: Q4 2020 in Review

AlphaCrest Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2020, closing a stake of 27,171 shares — an estimated $320K sold.

AlphaCrest Capital Management first reported a position in AERI in Q2 2019 and held it in 3 quarters. The position peaked at $481K in Q2 2019. 150 funds tracked by Wall St. Rank hold AERI as of Q4 2020.

AlphaCrest Capital Management reported no remaining Aerie Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
AlphaCrest Capital Management sold 27,171 Aerie Pharmaceuticals shares in Q4 2020, an estimated $320K.
AlphaCrest Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2019 and held it in 3 quarters.
AlphaCrest Capital Management's Aerie Pharmaceuticals position peaked at $481K in Q2 2019.
150 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2020.

Based on AlphaCrest Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.